A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxac096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Somi Cho und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Lupus Nephritis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Spleen tyrosine kinase (Syk) plays a pivotal role in the activation of B cells and innate inflammatory cells by transducing immune receptor-triggered signals. Dysregulated activity of Syk is implicated in the development of antibody-mediated autoimmune diseases including systemic lupus erythematosus (SLE) and rheumatoid arthritis, but the effect of Syk inhibition on such diseases remains to be fully evaluated. We have developed a novel selective Syk inhibitor, SKI-O-592, and its orally bioavailable salt form, SKI-O-703 (cevidoplenib). To examine the efficacy of SKI-O-703 on the progression of SLE, New Zealand black/white mice at the autoimmunity-established phase were administrated orally with SKI-O-703 for 16 weeks. Levels of IgG autoantibody, proteinuria, and glomerulonephritis fell significantly, and this was associated with hypoactivation of follicular B cells via the germinal center. In a model of serum-transferred arthritis, SKI-O-703 significantly ameliorated synovitis, with fewer neutrophils and macrophages infiltrated into the synovial tissue. This effect was recapitulated when mice otherwise refractory to anti-TNF therapy were treated by TNF blockade combined with a suboptimal dose of SKI-O-703. These results demonstrate that the novel selective Syk inhibitor SKI-O-703 attenuates the progression of autoantibody-mediated autoimmune diseases by inhibiting both autoantibody-producing and autoantibody-sensing cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
- Department of Anatomy and Cell Biology, College of Medicine, Hanyang University, Seoul 04763, Korea.
- Department of Discovery Biology, Research Institute, Oscotec Inc., Seongnam-si, Gyeonggi-do 13488, Korea.
ORCID-Profile: Eunkyeong Jang, Jeehee Youn
Zitieren
APA
Cho, S., Jang, E., Yoon, T., Hwang, H., & Youn, J. (2023). A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxac096
Vancouver
Cho S, Jang E, Yoon T, Hwang H, Youn J. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxac096
BibTeX
@article{Cho2023,
author = {Cho, Somi and Jang, Eunkyeong and Yoon, Taeyoung and Hwang, Haejun and Youn, Jeehee},
title = {A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxac096}
}
EUVIMED